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Poster  P resentat ions  - Sess ion  I 
ldlling and can be used to purge leukemic cells fi'om hematopoiet- 
ic stenr cell (HSC) products in an experimental nmrine transplan 
ration model. We now wish to extend our studies to examine the 
use of PS-341 administration post-HSC transplant. We hypothe- 
sized that PS-341 would reduce GVHD associated mortality by 
preventing degradation of IkB leading to decreased NF-kB DNA 
binding activity and NF-kB dependent cytokinc production. V~Ze 
tested tire efficacy of PS-341 administration i a full MHC mis- 
matched routine model of acute lethal GVHD. C57BL/6 bone 
marrow and splenocytes were transplanted into lethally irradiated 
BALB/c hosts. PS-341 (lmg/kg) was administered on the day of 
transplant and also at later time points in some groups. Under 
experimental conditions where animals that receive vehicle con- 
trol succumb to acute GVHD within 12 days of transplant, mice 
that received PS-34l on the day of transplant are protected from 
lethal disease (log rank test p< 0.0001). However, administration 
of PS-341 dur ing the first week post - t ransplant  resulted in 
markedly accelerated mortality due to GVHD.  These studies 
demonstrate that the proteasome inhibitor PS-341 can be given 
concurrent with allogeneic HSC transplantation and can reduce 
early lethal acute GVHD although timing of the administration is 
critical. 
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CML relapsing after allogencic stem cell transplantation (SCT) can 
be successfully retreated with DLI. However DLI can cause GVHD 
and is less effective for hematological relapse. We therefore used 
STI-571 to treat patients with CML relapsing after SCT following 
myelobalative preparative regimens. Ten patients (9 who had not 
received STI-571 pretransplant) relapsed 4-36 months post trans- 
plant. Five were molecular elapses, five were more advanced ( kary- 
otypic = 1, chronic phase (CP) = 2, blast crisis (BC) =2). STI-571 300- 
600 rag/day was given to all patients who had a minimum of two 
positive RT-PCR assays *2 months apart, or who developed hemato- 
logical relapse. Prior to treatment, immtmosuppression was stopped 
on all patients (n=9) without active GV~tD. STI as a single agent was 
given to 5 molecular eIapses. Two had failed prior DLI. Four 
patients prompdy became PCR negative within 6 weeks. However 
three had a molecular relapse after STI was stopped and are currently 
retreated. STI 571 combined with 1-5 xl07/kg CD3+ DLI was given 
to 5 patients relapsing with more advanced CML. Three (CP or kat T- 
otypic relapse) achieved complete molecular emissions, sustained in 
two. One myeloid BC patient developed extensive chronic GVHD 
after DLI given day 100 to treat persisting molecular disease, STI was 
stopped because of thrombocytopeuia, he progressed with chloromas 
by 5 months post-transplant but has achieved a stable molecular 
remission persisting >6 months after restarting STI 600rag/day. One 
patient relapsing in ALL BC achieved a hematological remission but 
relapsed again 3 months later and died of disease progTession.Thus, 
of I0 STI-txeated patients, 7achieved molecular remission which was 
sustained in 4. These results uggest hat the cytoreductive action of 
STI can synergize with the graft-versus-leukemia effect. However, 
the tendency for further elapse when STI is withdrawn suggests that 
cure of relapsed CML may also require a GVL effect. 
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INFUSION OF HIGH NUMBERS OF G-CSF MOBILIZED BLOOD DEN- 
DRITIC CELLS TYPE 2 (DC-2) IS ASSOCIATED WITH AN INCREASED 
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It was previously shown that dendritic cells type-2 (DC-2) are 
significantly increased in G-CSF-mobil ized leukapheresis prod- 
ucts as compared to unstimulated bone marrow. In this study, we 
analysed whether the numbers of DC-1 and DC-2, as well as of 
other cell components in the graft, was associated with acute 
and/or chronic GVI ID in 31 adult patients (11 MM, 7 CML CP, 
6 AML, 5 NHL,  and 2 MDS) receiving an allogeneic PBSC trans- 
plant from HLA-lnatched siblings. Average cell doses (xl06/kg) in 
the grafts were the following: 283_+137 CD3+ T ceils, 160_+88 
CD4+ T lymphocytes, 116_+55 CDS+ T lymphocytes, 64_+39 
CD19+ B lymphocytes, 51_+29 CD56+ NK cells, 253_+103 CD14+ 
monocytes, 6.6+4.1 CD34+ cells, 2.1_+0.9 HLA-DR+lin-CD i I c+ 
DC-1 and 2.9_+1.3 HLA-DR+lin-CD123+ DC-2. Median follow 
up was 255 days (range: 50-685). Patients were initially divided in 
three groups according to whether they had shown no signs of 
acute GVHD (grade 0, n=10), acute GVHD grade I (n=12), or 
grade II - IV (n=9). Median numbers of CD34+ cells, lymphocyte 
subsets, and DC-1 and DC-2 received by patients in these three 
groups did not differ significantly. Of 21 patients with adequate 
follow up (median 485 days, range: 131-695) 12 developed chronic 
GVHD (10 extensive, 2 limited). Analysis of cell components of 
the grafts demonstrated that patients developing chronic GVHD 
had received a signifcantly higher dose of DC-2 than patients 
without chronic GVHD (3.3+_1.5 vs 2.2_+0.9, p=0.05), while the 
dose of DC-1 (p=0.7), monocytes (p-0.28), T lymphocytes 
(p=0.643), B lymphocytes (p=0.939), NK  cells (p=0.487) and 
CD34+ cells (p=0.757) was not different. Also, chronic GVHD did 
not correlate with recipient or donor age or gender, interval 
between diagnosis and transplant, presence of ATG or TBI in the 
conditioning regimen, or type of GVHD prophylaxis. Our results 
suggest hat the presence of large DC-2 numbers in the graft may 
be associated with a higher risk of chronic GVHD after allogeneic 
PBSC transplantation. These data might prompt further studies 
addressing whether depletion of graft DC-2 might be beneficial in 
this setting. 
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A growing body of evidence suggests that functional unrespon- 
siveness of the immune system to growing solid tumors may be 
due to tolerance in minor-specific CD4 + T cells, whereas tumor 
specific CD8 + T cells exist in a state of partial activation with lim- 
ited effector function. We therefore hypothesized that an allo- 
geneie graft-versus host reaction may provide a helper effect that 
augments the anti-tumor immune response of host CD8 + T cells 
in mixed henaatopoietic chimeras. To test this hypothesis, we ana- 
lyzed host versus donor T cell responses to AH1, an H-2L 'u- 
restricted tumor antigen expressed by CT-26, a colon cancer of 
BALB/c mice. BALB/c mice with pre-established subcutaneous 
tumor underwent NST  from MHC-compatible B10.D2 donors. 
Two weeks later, groups of chimeras received nothing, B10.D2 
splenocytes IV, CT-26 tumor vaccine (irradiated CT-26 cells 
mixed with a GM-CSF secreting bystander cell line), or both. By 
staining with H-2L d tetramers loaded with the AHI 423-431 a.a. 
peptide, AHl-specific CD8 + T ceils were found to comprise 2-3% 
of total spleen CD8 + T cells three weeks after vaccination. In con- 
trast~ AHl-specific T cells could not be detected in the non-trans- 
planted, tumor hearing mice. To flirther characterize AHl-specif 
ic T cells we characterized T cell avidity for antigen, as measured 
, by binding ofAH1 peptide-loaded, L ~ IgG dinnners. AH1 specific 
T cells were easily expanded in vitro using AH-1 peptide pulsed 
irradiated BALB/c splenocytes. After four weeks of stimulation 
the highest percentages of cultures containing AHl-specif ic T 
cells were derived from tumor-bearing chimeras that received 
B10.D2 splenocytes and a CT-26 vaccine. Expanded cultures con- 
tained AH-1 specific CD8 + T cells derived front the host and the 
donor, based on the differential expression of Ly9.1 marker on the 
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